Remicade drives Mitsubishi Tanabe's nine-month growth
This article was originally published in Scrip
The TNF-targeting antibody Remicade (infliximab) was again the star performer for Mitsubishi Tanabe Pharma (MTP) in the third quarter, helping the Japanese firm overcome lower sales for a number of older prescription drugs.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.